Clinical trial · no report yet · Phase 2
BELLINI
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
- NCT03815890 ↗
- Recruiting
- The Netherlands Cancer Institute
- 89 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 38 | |
| X threads | 29 | |
| Podcasts | 21 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Pre-operative Phase II Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI Trial)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer
- Interventions
- Nivolumab; Ipilimumab; Ipilimumab
- Arms
- 1A; LumB · Experimental
- 1B; TNBC · Experimental
- 2A; LUMB · Experimental
- 2B; TNBC · Experimental
- 3B; TNBC, High TIL · Experimental
- Enrollment
- 80 (estimated)
- Primary outcomes
- Pathological complete response rate per cohort,
- Sponsor
- The Netherlands Cancer Institute with Bristol-Myers Squibb
- Start
- Oct 4, 2019
- Primary completion
- Jan 1, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT03815890 · updated May 30, 2024
Publications
linked from the registry- Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med. 2024 Nov;30(11):3223-3235. doi: 10.1038/s41591-024-03249-3. Epub 2024 Sep 16. PubMed 39284953